LOS ANGELES, Oct. 3, 2023 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen’s CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® (panitumumab), a targeted therapy used in the treatment of colorectal cancer. This landmark…
EntroGen Receives FDA Approval for CRCdx® RAS Mutation Detection Kit as Companion Diagnostic for Vectibix®
This post was originally published on this site